Source 1primary paper2025MED
Toolkit/cytokine armoring
cytokine armoring
Also known as: IL-15 armoring
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Key innovations in engineered NK cell therapies-including CAR-NK, cytokine armoring (e.g., IL-15), and bispecific/trispecific NK cell engagers (NKCEs)-are critically evaluated.
Usefulness & Problems
Why this is useful
Cytokine armoring is presented as an engineered NK innovation, with IL-15 given as an example. In the abstract it is grouped with other strategies intended to improve NK therapeutic performance.; engineered NK enhancement strategies; improving NK cell durability
Source:
Cytokine armoring is presented as an engineered NK innovation, with IL-15 given as an example. In the abstract it is grouped with other strategies intended to improve NK therapeutic performance.
Source:
engineered NK enhancement strategies
Source:
improving NK cell durability
Problem solved
The review discusses strategies to enhance homing, infiltration, and durability, and cytokine armoring is one of the highlighted engineering innovations.; supports strategies to enhance durability
Source:
The review discusses strategies to enhance homing, infiltration, and durability, and cytokine armoring is one of the highlighted engineering innovations.
Source:
supports strategies to enhance durability
Problem links
supports strategies to enhance durability
LiteratureThe review discusses strategies to enhance homing, infiltration, and durability, and cytokine armoring is one of the highlighted engineering innovations.
Source:
The review discusses strategies to enhance homing, infiltration, and durability, and cytokine armoring is one of the highlighted engineering innovations.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
translationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
example cytokine named is IL-15
abstract does not specify construct-level tradeoffs
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review summarizes promising trial outcomes including 83% remission in lymphoma with CAR19-NK.
remission rate 83 %
NK cells offer reduced toxicity and off-the-shelf potential relative to CAR-T therapies.
Strategies to enhance homing, infiltration, and durability are discussed for engineered NK cell therapies.
CAR-NK therapy is presented as a paradigm shift in immuno-oncology that is augmented by NKCEs and cytokine armoring.
Future directions in engineered NK therapy include logic-gated CARs, iPSC-derived NK platforms, and combinations with immune checkpoint blockade.
Antigen escape remains a shared limitation of both CAR-T and engineered NK cell therapies.
NK cell-based therapies address safety challenges associated with CAR-T, including reduced CRS and GvHD.
Engineered NK cell therapies face translational barriers from tumor microenvironment immunosuppression, metabolic constraints, and NK cell exhaustion.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug cytokine-armoring
Key innovations in engineered NK cell therapies-including CAR-NK, cytokine armoring (e.g., IL-15), and bispecific/trispecific NK cell engagers (NKCEs)-are critically evaluated.
Source:
engineering strategysupports
Strategies to enhance homing, infiltration, and durability are discussed for engineered NK cell therapies.
Source:
field positioningsupports
CAR-NK therapy is presented as a paradigm shift in immuno-oncology that is augmented by NKCEs and cytokine armoring.
Source:
translational barriersupports
Engineered NK cell therapies face translational barriers from tumor microenvironment immunosuppression, metabolic constraints, and NK cell exhaustion.
Source:
Comparisons
Source-stated alternatives
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Source:
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Source-backed strengths
presented as a key innovation in engineered NK therapies
Source:
presented as a key innovation in engineered NK therapies
Compared with CAR-NK
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a key innovation in engineered NK therapies.
Relative tradeoffs: abstract does not specify construct-level tradeoffs.
Source:
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Compared with chimeric antigen receptor natural killer cells
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a key innovation in engineered NK therapies.
Relative tradeoffs: abstract does not specify construct-level tradeoffs.
Source:
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Compared with NK cell engagers
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as a key innovation in engineered NK therapies.
Relative tradeoffs: abstract does not specify construct-level tradeoffs.
Source:
The abstract discusses CAR-NK and NKCEs alongside cytokine armoring as alternative or complementary engineered NK approaches.
Ranked Citations
- 1.